Primary sclerosing cholangitis

Jayant A. Talwalkar, Keith Lindor

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts. An estimated 80% of patients in North America and Europe have coexistent inflammatory bowel disease (IBD). The underlying pathophysiology of PSC remains poorly understood. As a result, there is currently no effective medical therapy to halt disease progression. Important complications from PSC include metabolic bone disease, colorectal neoplasia, and cholangiocarcinoma. Liver transplantation remains the only successful treatment option for patients with advanced liver disease from PSC. A diagnosis of PSC should be considered among individuals with IBD and elevated serum liver biochemical tests.

Original languageEnglish (US)
Pages (from-to)62-72
Number of pages11
JournalInflammatory Bowel Diseases
Volume11
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Inflammatory Bowel Diseases
Liver Diseases
Intrahepatic Bile Ducts
Extrahepatic Bile Ducts
Cholangiocarcinoma
Metabolic Bone Diseases
North America
Liver Transplantation
Disease Progression
Fibrosis
Inflammation
Liver
Therapeutics
Serum
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Primary sclerosing cholangitis. / Talwalkar, Jayant A.; Lindor, Keith.

In: Inflammatory Bowel Diseases, Vol. 11, No. 1, 01.2005, p. 62-72.

Research output: Contribution to journalArticle

Talwalkar, Jayant A. ; Lindor, Keith. / Primary sclerosing cholangitis. In: Inflammatory Bowel Diseases. 2005 ; Vol. 11, No. 1. pp. 62-72.
@article{a5fc3c4280564ba3b4e7849aa0160b00,
title = "Primary sclerosing cholangitis",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts. An estimated 80{\%} of patients in North America and Europe have coexistent inflammatory bowel disease (IBD). The underlying pathophysiology of PSC remains poorly understood. As a result, there is currently no effective medical therapy to halt disease progression. Important complications from PSC include metabolic bone disease, colorectal neoplasia, and cholangiocarcinoma. Liver transplantation remains the only successful treatment option for patients with advanced liver disease from PSC. A diagnosis of PSC should be considered among individuals with IBD and elevated serum liver biochemical tests.",
author = "Talwalkar, {Jayant A.} and Keith Lindor",
year = "2005",
month = "1",
doi = "10.1097/00054725-200501000-00009",
language = "English (US)",
volume = "11",
pages = "62--72",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Primary sclerosing cholangitis

AU - Talwalkar, Jayant A.

AU - Lindor, Keith

PY - 2005/1

Y1 - 2005/1

N2 - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts. An estimated 80% of patients in North America and Europe have coexistent inflammatory bowel disease (IBD). The underlying pathophysiology of PSC remains poorly understood. As a result, there is currently no effective medical therapy to halt disease progression. Important complications from PSC include metabolic bone disease, colorectal neoplasia, and cholangiocarcinoma. Liver transplantation remains the only successful treatment option for patients with advanced liver disease from PSC. A diagnosis of PSC should be considered among individuals with IBD and elevated serum liver biochemical tests.

AB - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts. An estimated 80% of patients in North America and Europe have coexistent inflammatory bowel disease (IBD). The underlying pathophysiology of PSC remains poorly understood. As a result, there is currently no effective medical therapy to halt disease progression. Important complications from PSC include metabolic bone disease, colorectal neoplasia, and cholangiocarcinoma. Liver transplantation remains the only successful treatment option for patients with advanced liver disease from PSC. A diagnosis of PSC should be considered among individuals with IBD and elevated serum liver biochemical tests.

UR - http://www.scopus.com/inward/record.url?scp=13944267536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944267536&partnerID=8YFLogxK

U2 - 10.1097/00054725-200501000-00009

DO - 10.1097/00054725-200501000-00009

M3 - Article

VL - 11

SP - 62

EP - 72

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -